A 3-day schedule of 5-fluorouracil and folinic acid in metastatic progressive colorectal cancer and its impact in terms of palliation.

C. Schöber, H. Poliwoda, Michael Ståhl(Berlin Institute of Health at Charité - Universitätsmedizin Berlin), Hans‐Joachim Wilke(Helmholtz-Institute Ulm), Hans‐Joachim Schmoll(Martin Luther University Halle-Wittenberg), C.H. Köhne-Wömpner

PubMed

April 1, 1992

Cited by 2

Related Papers

ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making

|Annals of Oncology|2012|1.5k

Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial

|The Lancet Oncology|2012|526

Characterization of the rapamycin-sensitive phosphoproteome reveals that Sch9 is a central coordinator of protein synthesis

|Genes & Development|2009|351

Outcome according to KRAS-, NRAS- and BRAF-mutation as well as KRAS mutation variants: pooled analysis of five randomized trials in metastatic colorectal cancer by the AIO colorectal cancer study group

|Annals of Oncology|2016|344

Phase III Study of Capecitabine Plus Oxaliplatin Compared With Fluorouracil and Leucovorin Plus Oxaliplatin in Metastatic Colorectal Cancer: A Final Report of the AIO Colorectal Study Group

|Journal of Clinical Oncology|2007|281